Skip to search formSkip to main contentSkip to account menu

lifibrol

Known as: 4-(4'-tert-butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol 
A novel lipid-lowering agent with a complicated mechanism of action. Lifibrol may affect bile acid metabolism, enhance sterol excretion, reduce… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

ButanolsHydroxybenzoates

Narrower (1)

K 12.148

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Safety and efficacy of lifibrol upon four-week administration to patients with primary hypercholesterolaemia
The efficacy and safety of lifibrol, a novel cholesterol-lowering drug, was investigated in a double-blind clinical study in 168… 
Review
2003
Review
2003
Pharmacotherapy for dyslipidaemia – current therapies and future agents
Current lipid-altering agents that lower low density lipoprotein cholesterol (LDL-C) primarily through increased hepatic LDL… 
1999
1999
Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol
Lifibrol is a powerful cholesterol‐lowering drug of unknown mechanism of action. This investigation was carried out to determine… 
1997
1997
Lifibrol: first member of a new class of lipid-lowering drugs?
Management of dyslipoproteinaemia is one of the key strategies in the prevention of cardiovascular disease. The major target of… 
1996
1996
Biotransformation of lifibrol (U-83860) to mixed glyceride metabolites by rat and human hepatocytes in primary culture.
Lifibrol (U-83860), K12.148) is a lipid-lowering drug that has the potential to accumulate in the liver and induce hepatic… 
1995
1995
A novel assay for cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase activity using reversed-phase ion-pair chromatography: demonstration that Lifibrol (K12.148) modulates the enzyme activity.
Cytosolic HMG-CoA synthase and microsomal 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase catalyze two sequential steps in the… 
1995
1995
Lifibrol: A novel lipid‐lowering drug for the therapy of hypercholesterolemia
1994
1994
Chiral assay methods for lifibrol and metabolites in plasma and the observation of unidirectional chiral inversion following administration of the enantiomers to dogs.
Lifibrol, a new drug for the treatment of hypercholesterolemia, contains a stereogenic center bearing a secondary alcohol group… 
1994
1994
Comparison of lifibrol to other lipid-regulating agents in experimental animals.
1990
1990
The hypolipidemic effect of lifibrol during a long term treatment of pigs.
We investigated the hypolipidemic property of lifibrol in male and female minipigs in a long term trial over a treatment period… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)